Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module

Abstract Neuropsychiatric complications associated with coronavirus disease 2019 caused by the Coronavirus SARS-CoV-2 (COVID-19) are increasingly appreciated. While most studies have focussed on severely affected individuals during acute infection, it remains unclear whether mild COVID-19 results in neurocognitive deficits in young patients. Here, we established a screening approach to detect cognitive deficiencies in post-COVID-19 patients. In this cross-sectional study, we recruited 18 mostly young patients 20–105 days (median, 85 days) after recovery from mild to moderate disease who visited our outpatient clinic for post-COVID-19 care. Notably, 14 (78%) patients reported sustained mild cognitive deficits and performed worse in the Modified Telephone Interview for Cognitive Status screening test for mild cognitive impairment compared to 10 age-matched healthy controls. While short-term memory, attention and concentration were particularly affected by COVID-19, screening results did not correlate with hospitalization, treatment, viremia or acute inflammation. Additionally, Modified Telephone Interview for Cognitive Status scores did not correlate with depressed mood or fatigue. In two severely affected patients, we excluded structural or other inflammatory causes by magnetic resonance imaging, serum and cerebrospinal fluid analyses. Together, our results demonstrate that sustained sub-clinical cognitive impairments might be a common complication after recovery from COVID-19 in young adults, regardless of clinical course that were unmasked by our diagnostic approach.

Download Full-text

Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson’s Disease

Frontiers in Aging Neuroscience ◽

10.3389/fnagi.2021.656623 ◽

2021 ◽

Vol 13 ◽

Author(s):

Megan C. Bakeberg ◽

Anastazja M. Gorecki ◽

Jade E. Kenna ◽

Alexa Jefferson ◽

Michelle Byrnes ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Cognitive Function ◽

Cognitive Performance ◽

Linear Models ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Cognitive Status ◽

Cross Sectional ◽

Age Related

IntroductionCholesterol levels have been associated with age-related cognitive decline, however, such an association has not been comprehensively explored in people with Parkinson’s disease (PD). To address this uncertainty, the current cross-sectional study examined the cholesterol profile and cognitive performance in a cohort of PD patients.MethodsCognitive function was evaluated using two validated assessments (ACE-R and SCOPA-COG) in 182 people with PD from the Australian Parkinson’s Disease Registry. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Triglyceride (TRG) levels were examined within this cohort. The influence of individual lipid subfractions on domain-specific cognitive performance was investigated using covariate-adjusted generalised linear models.ResultsFemales with PD exhibited significantly higher lipid subfraction levels (TC, HDL, and LDL) when compared to male counterparts. While accounting for covariates, HDL levels were strongly associated with poorer performance across multiple cognitive domains in females but not males. Conversely, TC and LDL levels were not associated with cognitive status in people with PD.ConclusionHigher serum HDL associates with poorer cognitive function in females with PD and presents a sex-specific biomarker for cognitive impairment in PD.

Download Full-text

Gangguan Kognitif pada Pasien Pasca Sembuh Dari Covid-19

Syntax Literate ; Jurnal Ilmiah Indonesia ◽

10.36418/syntax-literate.v6i6.3151 ◽

2021 ◽

Vol 6 (6) ◽

pp. 2935

Author(s):

Ni Made Gitaria Sylvana Ratmadewi ◽

Rudy Dwi Laksono ◽

Laura Bianca Sylvia Huwae

Keyword(s):

Random Sampling ◽

Telephone Interview ◽

Cognitive Status ◽

Cross Sectional ◽

Blood Brain

Pasien yang sembuh dari Covid-19 memiliki beberapa keluhan pada daya ingat. Virus corona dapat menembus ke SSP (Sistem Saraf Pusat) dan cairan serebrospinal dalam waktu kurang dari seminggu. Pemeriksaan histopatologi otak pasien Covid-19 yang meninggal menunjukkan potensi SARS-CoV-2 menginfeksi ke sistem saraf pusat (SSP). Neuro inflamasi juga dapat merusak BBB (Blood Brain Barier). Setelah BBB terganggu, sitokin dapat masuk ke SSP dan menyebabkan aktivasi mikroglial dan stres oksidatif, yang menyebabkan gangguan kognitif. Metode Penelitian dilakukan secara cross sectional random sampling terhadap pasien di Ruang Isolasi Covid-19 Rumah Sakit Tingkat II. Prof. dr. J.A Latumeten Ambon selama periode Maret 2020 sampai dengan Maret 2021 dengan melakukan wawancara menggunakan Telephone Interview for Cognitive Status-M (TICS-M) yang terdiri dari 22 pertanyaan dengan total nilai 50. Dari 167 pasien, terdapat 54 pasien yang bersedia di wawancara dan terdapat 28 pasien yang memiliki kecenderungan gangguan cognitive ringan dengan rentang usia 31-40 tahun. Penelitian ini menemukan bahwa nilai TICS-M pada pasien pasca Covid-19 berhubungan dengan usia, namun tidak berhubungan dengan jenis kelamin dan lamanya pendidikan.

Download Full-text

The M. D. Anderson Symptom Inventory–Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2008.02.072 ◽

2008 ◽

Vol 72 (5) ◽

pp. 1355-1361 ◽

Cited By ~ 45

Author(s):

David I. Rosenthal ◽

Tito R. Mendoza ◽

Mark S. Chambers ◽

V. Shannon Burkett ◽

Adam S. Garden ◽

...

Keyword(s):

Head And Neck ◽

Patient Reported Outcome ◽

Symptom Inventory ◽

Outcome Instrument ◽

Patient Reported ◽

Radiation Induced

Download Full-text

Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home—Results From a Pilot Study

JCO Clinical Cancer Informatics ◽

10.1200/cci.17.00125 ◽

2018 ◽

pp. 1-15 ◽

Cited By ~ 8

Author(s):

Pasquale Innominato ◽

Sandra Komarzynski ◽

Abdoulaye Karaboué ◽

Ayhan Ulusakarya ◽

Mohamed Bouchahda ◽

...

Keyword(s):

Body Weight ◽

Real Time ◽

Outcome Measures ◽

Patient Reported Outcome Measures ◽

Patient Reported Outcome ◽

Symptom Inventory ◽

Home Based ◽

Patient Reported ◽

Md Anderson ◽

At Home

Purpose To assess the impact of chronomodulated irinotecan fluorouracil-leucovorin and oxaliplatin (chronoIFLO4) delivered at home on the daily life of patients with cancer in real time using a home-based e-Health multifunction and multiuser platform. This involved multidimensional telemonitoring of circadian rest-activity rhythm (CircAct), sleep, patient-reported outcome measures, and body weight changes (BWCs). Patients and Methods Patients received chronoIFLO4 fortnightly at home. Patients completed the 19-item MD Anderson Symptom Inventory on an interactive electronic screen, weighed themselves on a dedicated scale, and continuously wore a wrist accelerometer for CircAct and sleep monitoring. Daily data were securely teletransmitted to a specific server accessible by the hospital team. The clinically relevant CircAct parameter dichotomy index I < O and sleep efficiency (SE) were calculated. The dynamic patterns over time of patient-reported outcome measures, BWC, I < O, and SE informed the oncology team on tolerance in real time. Results The platform was installed in the home of 11 patients (48 to 72 years of age; 45% men; 27% with performance status = 0), who were instructed on its use on site. They received 26 cycles and provided 5,891 data points of 8,736 expected (67.4%). The most severe MD Anderson Symptom Inventory scores were: interference with work (mean: 5.1 of 10) or general activity (4.9), fatigue (4.9), distress (4.2), and appetite loss (3.6). Mean BWC was −0.9%, and mean SE remained > 82%. CircAct disruption (I < O ≤ 97.5%) was observed in four (15%) cycles before chronoIFLO4 start and in five (19%) cycles at day 14. Conclusion The patient-centered multidimensional telemonitoring solution implemented here was well accepted by patients receiving multidrug chemotherapy at home. Moreover, it demonstrated that chronoIFLO4 was a safe therapeutic option. Such integrated technology allows the design of innovative management approaches, ultimately improving patients’ experience with chemotherapy, wellbeing, and outcomes.

Download Full-text